Your Cart

Imagion Biosystems Market Herald Interview

Imagion Biosystems Market Herald Interview

We recently announced plans to conduct our first in-human study for MagSense in Australia later this year.

In this Market Herald interview, watch IBX CEO Bob Proulx describe why Australia’s favourable clinical environment and the ability to expand the study to include MRI make Australia the ideal setting for this upcoming study.

Watch the interview:

Related Articles

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.